Robert E. Reiter

22.6k total citations · 9 hit papers
234 papers, 12.0k citations indexed

About

Robert E. Reiter is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Robert E. Reiter has authored 234 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Pulmonary and Respiratory Medicine, 89 papers in Radiology, Nuclear Medicine and Imaging and 33 papers in Cancer Research. Recurrent topics in Robert E. Reiter's work include Prostate Cancer Treatment and Research (157 papers), Prostate Cancer Diagnosis and Treatment (116 papers) and Radiopharmaceutical Chemistry and Applications (48 papers). Robert E. Reiter is often cited by papers focused on Prostate Cancer Treatment and Research (157 papers), Prostate Cancer Diagnosis and Treatment (116 papers) and Radiopharmaceutical Chemistry and Applications (48 papers). Robert E. Reiter collaborates with scholars based in United States, Canada and Germany. Robert E. Reiter's co-authors include Daniel Margolis, Jiaoti Huang, Steven S. Raman, Leonard S. Marks, Owen N. Witte, Joyce M. Yamashiro, Jonathan Said, Charles L. Sawyers, Shyam Natarajan and Lorna Kwan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Robert E. Reiter

224 papers receiving 11.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prostate cancer

2021 663 citations David C. Johnson, Robert E. Reiter et al. profile →
Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer

1998 556 citations Robert E. Reiter, George Thomas et al. profile →
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

1998 526 citations Robert E. Reiter, Jonathan Said et al. profile →
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

2017 386 citations Jérémie Calais, Thomas A. Hope et al. profile →
Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology

2014 336 citations Lorna Kwan, Leonard S. Marks et al. European Urology profile →
Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsies

2016 305 citations Shyam Natarajan, Robert E. Reiter et al. Cancer profile →
Value of Targeted Prostate Biopsy Using Magnetic Resonance–Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen

2013 297 citations Geoffrey A. Sonn, Shyam Natarajan et al. European Urology profile →
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

2023 127 citations Jérémie Calais, Robert E. Reiter et al. European Urology profile →
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging

2025 19 citations Nicholas G. Nickols, Amar U. Kishan et al. profile →

Peers

Countries citing papers authored by Robert E. Reiter

Since Specialization

Citations

This map shows the geographic impact of Robert E. Reiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Reiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Reiter more than expected).

Fields of papers citing papers by Robert E. Reiter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Reiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Reiter. The network helps show where Robert E. Reiter may publish in the future.

Co-authorship network of co-authors of Robert E. Reiter

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Reiter. A scholar is included among the top collaborators of Robert E. Reiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Reiter. Robert E. Reiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantitative 3-T Multiparametric MRI Parameters as Predictors of Aggressive Prostate Cancer 2025 ·Radiology Imaging Cancer ·Daniel H. Kim, Ida Sonni, Tristan Grogan, Anthony Sisk, Vishnu Murthy, William Hsu, Kyunghyun Sung, David Lu, Robert E. Reiter, Steven S. Raman	1
2	Identifying cribriform and intraductal histology on magnetic resonance imaging‐assisted biopsy for patients with intermediate‐grade prostate cancer: Implications for active surveillance 2025 ·Cancer ·(unknown), (unknown), (unknown), Timothy J. Daskivich, Steven S. Raman, Anthony Sisk, Wayne Brisbane, Robert E. Reiter, Adam B. Weiner	0
3	Surgical techniques for enhancing postoperative urinary continence in robot-assisted radical prostatectomy: a comprehensive review 2025 ·International Journal of Surgery ·Yufei Yu, Robert E. Reiter, Mo Zhang	0
4	Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial 2024 ·European Urology Open Science ·Adam B. Weiner, (unknown), Catherine Meyer, (unknown), (unknown), (unknown), (unknown), Giuseppe Carlucci, Robin Grant, Johannes Czernin, Jérémie Calais, Robert E. Reiter	2
5	Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial 2024 ·European Urology ·(unknown), Matthew B. Rettig, John Shen, Robert E. Reiter, Alan Lee, Michael L. Steinberg, Luca Valle, (unknown), Tahmineh Romero, Jérémie Calais, Johannes Czernin, Nicholas G. Nickols, Amar U. Kishan	10
6	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT 2022 ·Prostate Cancer and Prostatic Diseases ·(unknown), Tahmineh Romero, (unknown), Matthew B. Rettig, Michael L. Steinberg, Amar U. Kishan, Dörthe Schaue, Robert E. Reiter, Beatrice S. Knudsen, Nicholas G. Nickols	10
7	High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors 2020 ·Clinical Cancer Research ·Lin Lin, (unknown), Naoko Kobayashi, Evelyn A. Kono, Joyce M. Yamashiro, Nicholas G. Nickols, Robert E. Reiter	57
8	Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial 2020 ·European Urology Open Science ·Justin Ferdinandus, Wolfgang P. Fendler, Jérémie Calais, (unknown), Robert R. Flavell, Ashley Mishoe, (unknown), Hao G. Nguyen, Robert E. Reiter, Matthew B. Rettig, J Gartmann, (unknown), Eric J. Small, Roger Slavik, Peter R. Carroll, Karin A. Herrmann, Johannes Czernin, Thomas A. Hope	2
9	Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer 2020 ·Molecular Imaging and Biology ·Wen‐Ting K. Tsai, Kirstin A. Zettlitz, Magnus Dahlbom, Robert E. Reiter, Anna M. Wu	10
10	Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection 2019 ·Cancer ·David C. Johnson, (unknown), Lorna Kwan, (unknown), Sohrab Afshari Mirak, Aydin Pooli, (unknown), (unknown), Steve Zhou, Alan Priester, Shyam Natarajan, Amirhossein Mohammadian Bajgiran, Sepideh Shakeri, Anthony Sisk, Ely Felker, Steven S. Raman, Leonard S. Marks, Robert E. Reiter	24
11	Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models 2018 ·Clinical Cancer Research ·Mo Zhang, Naoko Kobayashi, Kirstin A. Zettlitz, Evelyn A. Kono, Joyce M. Yamashiro, Wen‐Ting K. Tsai, Ziyue Karen Jiang, Chau P. Tran, Chung Wang, (unknown), Anna M. Wu, Robert E. Reiter	26
12	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer 2017 ·OncoImmunology ·Saul J. Priceman, Ethan Gerdts, Dileshni Tilakawardane, (unknown), John P. Murad, Anthony K. Park, Brook Jeang, Yukiko Yamaguchi, Xin Yang, Ryan Urak, Lihong Weng, Wen-Chung Chang, Sarah Wright, Sumanta K. Pal, Robert E. Reiter, Anna M. Wu, Christine E. Brown, Stephen J. Forman	120
13	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer 2017 ·Urology ·John V. Hegde, Darlene Veruttipong, Jonathan Said, Robert E. Reiter, Michael L. Steinberg, Christopher R. King, Amar U. Kishan	4
14	Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time 2015 ·Clinical Cancer Research ·Geoffrey A. Sonn, (unknown), Ziyue Karen Jiang, Kirstin A. Zettlitz, Eric J. Lepin, Laurent A. Bentolila, Scott M. Knowles, (unknown), Anna M. Wu, Robert E. Reiter	41
15	Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer 2014 ·Clinical Cancer Research ·Scott M. Knowles, Richard Tavaré, Kirstin A. Zettlitz, Matthew M. Rochefort, Felix B. Salazar, Ziyue Karen Jiang, Robert E. Reiter, Anna M. Wu	25
16	Methoden und Werkzeuge der Digitalen Fabrik für den Mittelstand 2010 ·Zeitschrift für wirtschaftlichen Fabrikbetrieb ·(unknown), (unknown), Robert E. Reiter	4
17	Androgen Receptor and Invasion in Prostate Cancer 2008 ·Cancer Research ·Takahito Hara, Hideyo Miyazaki, Aram Lee, Chau P. Tran, Robert E. Reiter	98
18	Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer 2004 ·Clinical Cancer Research ·George Thomas, Steve Horvath, Bradley L. Smith, Katherine Crosby, (unknown), Matthew Schrage, Jonathan W. Said, Jean De Kernion, Robert E. Reiter, Charles L. Sawyers	54
19	Role of prostate stem cell antigen in prostate cancer research 2002 ·Current Opinion in Urology ·Mark Jalkut, Robert E. Reiter	23
20	Chromosome 17p deletions and p53 mutations in renal cell carcinoma. 1993 ·PubMed ·Robert E. Reiter, Patrick Anglard, (unknown), James R. Gnarra, W. Marston Linehan	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact